Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters
This study is currently recruiting participants.
Verified April 2013 by Upsher-Smith Laboratories
Sponsor:
Upsher-Smith Laboratories
Information provided by (Responsible Party):
Upsher-Smith Laboratories
ClinicalTrials.gov Identifier:
NCT01529034
First received: February 3, 2012
Last updated: April 16, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
| Condition | Intervention | Phase |
|---|---|---|
|
Epilepsy |
Drug: USL261 |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Primary Purpose: Treatment |
| Official Title: | An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters |
Resource links provided by NLM:
Genetics Home Reference related topics:
pyridoxal 5'-phosphate-dependent epilepsy
U.S. FDA Resources
Further study details as provided by Upsher-Smith Laboratories:
Primary Outcome Measures:
- Long-term safety and tolerability [ Designated as safety issue: Yes ]Adverse events, clinical laboratory assessments, sedation, vital signs, physical exams, C-SSRS
Secondary Outcome Measures:
- Treatment Success [ Designated as safety issue: No ]Termination of seizure(s) within 10 minutes and no recurrence within 4 hours after study drug administration
| Estimated Enrollment: | 155 |
| Study Start Date: | July 2012 |
| Estimated Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: USL261 | Drug: USL261 |
Eligibility| Ages Eligible for Study: | 14 Years to 66 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Has a competent, adult caregiver who can recognize and observe the subject's seizure cluster episodes
- Has successfully completed study P261-401, and the subject and caregiver have demonstrated adequate compliance with P261-401 study procedures as determined by the investigator
Exclusion Criteria:
- Has experienced status epilepticus during or since the P261-401 study
- In the opinion of the investigator, is experiencing an ongoing, uncontrolled, clinically significant adverse event(s) from P261-401 at Visit 1 or did experience a clinically significant adverse event in study P261-401 that might prevent the subject from safely participating in the study
- Has a neurological disorder that is likely to progress in the next year
- Has a history of acute narrow-angle glaucoma
- Has a medical condition including uncontrolled cardiac, pulmonary, renal, hepatic, or gastrointestinal disease that could interfere with the study, subject safety/safety monitoring, or is not stable despite current therapy
- Subject has severe chronic cardio-respiratory disease or the need for ambulatory oxygen
- Has had psychogenic, non-epileptic seizure(s) during or since the P261-401 study
- Has active suicidal plan or intent as determined by the C-SSRS at Visit 1 or medical history
- Subject has had vagus nerve stimulator (VNS) implanted since the completion of study P261-401
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01529034
Hide Study Locations
Contacts
| Contact: Gerrit Ross | 1-866-372-0526 |
Hide Study LocationsLocations
| United States, Arizona | |
| United States, Arizona | Recruiting |
| Phoenix, Arizona, United States | |
| Contact 866-372-0526 | |
| United States, Arkansas | |
| United States, Arkansas | Recruiting |
| Little Rock, Arkansas, United States | |
| Contact 866-372-0526 | |
| United States, California | |
| United States, California | Recruiting |
| Ventura, California, United States | |
| Contact 866-372-0526 | |
| United States, Colorado | |
| United States, Colorado | Recruiting |
| Aurora, Colorado, United States | |
| Contact 866-372-0526 | |
| United States, Florida | |
| United States, Florida | Recruiting |
| Gulf Breeze, Florida, United States | |
| Contact 866-372-0526 | |
| United States, Florida | Recruiting |
| Tampa, Florida, United States | |
| Contact 866-372-0526 | |
| United States, Florida | Recruiting |
| Wellington, Florida, United States | |
| Contact 866-372-0526 | |
| United States, Idaho | |
| United States, Idaho | Recruiting |
| Boise, Idaho, United States | |
| Contact 866-372-0526 | |
| United States, Kansas | |
| United States, Kansas | Recruiting |
| Manhattan, Kansas, United States | |
| Contact 866-372-0526 | |
| United States, Michigan | |
| United States, Michigan | Recruiting |
| Detroit, Michigan, United States | |
| Contact 866-372-0526 | |
| United States, Minnesota | |
| United States, Minnesota | Recruiting |
| St. Paul, Minnesota, United States | |
| Contact 866-372-0526 | |
| United States, Missouri | |
| United States, Missouri | Recruiting |
| St. Louis, Missouri, United States | |
| Contact 866-372-0526 | |
| United States, New Jersey | |
| United States, New Jersey | Recruiting |
| Hackensack, New Jersey, United States | |
| Contact 866-372-0526 | |
| United States, New York | |
| United States, New York | Recruiting |
| Bronx, New York, United States | |
| Contact 866-372-0526 | |
| United States, North Carolina | |
| United States, North Carolina | Recruiting |
| Durham, North Carolina, United States | |
| Contact 866-372-0526 | |
| United States, Oklahoma | |
| United States, Oklahoma | Recruiting |
| Oklahoma City, Oklahoma, United States | |
| Contact 866-372-0526 | |
| United States, Pennsylvania | |
| United States, Pennsylvania | Recruiting |
| Philadelphia, Pennsylvania, United States | |
| Contact 866-372-0526 | |
| United States, Tennessee | |
| United States, Tennessee | Recruiting |
| Nashville, Tennessee, United States | |
| Contact 866-372-0526 | |
| United States, Texas | |
| United States, Texas | Recruiting |
| Dallas, Texas, United States | |
| Contact 866-372-0526 | |
| Australia, Victoria | |
| Australia, Victoria | Recruiting |
| Parkville, Victoria, Australia | |
| Contact 1-800-881-011 | |
| Contact 1-800-551-155 | |
| Canada, Ontario | |
| Canada, Toronto | Recruiting |
| Toronto, Ontario, Canada | |
| Contact 866-372-0526 | |
| Canada, Quebec | |
| Canada, Quebec | Recruiting |
| Montreal, Quebec, Canada | |
| Contact 866-372-0526 | |
| Germany | |
| Germany, Bonn | Recruiting |
| Nordrhein-Westfalen, Bonn, Germany | |
| Contact 0-800-225-5288 | |
| Spain | |
| Spain, Andalucia | Recruiting |
| Sevilla, Andalucia, Spain | |
| Contact 866-372-0526 ext 900-99-0011 | |
| Spain, Catalonia | Recruiting |
| Tarassa, Catalonia, Spain | |
| Contact 866-372-0526 ext 900-99-0011 | |
| Spain, Madrid | Recruiting |
| Mirasierra, Madrid, Spain | |
| Contact 866-372-0526 ext 900-99-0011 | |
| Spain, Madrid | Recruiting |
| Madrid, Spain | |
| Contact 866-372-0526 ext 900-99-0011 | |
| Ukraine | |
| Ukraine, Kharkiv | Recruiting |
| Kharkiv, Ukraine | |
| Contact 0^00-11 | |
| Ukraine, Kharkiv | Recruiting |
| Kharkiv, Ukraine | |
| Contact 866-372-0526 ext 0^00-11 | |
| Ukraine, Ternopil | Recruiting |
| Ternopil, Ukraine | |
| Contact 866-372-0526 ext 0^00-11 | |
| Ukraine, Vinnytsa | Recruiting |
| Vinnytsa, Ukraine | |
| Contact 866-372-0526 ext 0^00-11 | |
Sponsors and Collaborators
Upsher-Smith Laboratories
More Information
No publications provided
| Responsible Party: | Upsher-Smith Laboratories |
| ClinicalTrials.gov Identifier: | NCT01529034 History of Changes |
| Other Study ID Numbers: | P261-402, 2011-004109-25 |
| Study First Received: | February 3, 2012 |
| Last Updated: | April 16, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Upsher-Smith Laboratories:
|
Epilepsy seizure clusters acute repetitive seizures rescue treatment |
Additional relevant MeSH terms:
|
Epilepsy Seizures Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Neurologic Manifestations Signs and Symptoms |
ClinicalTrials.gov processed this record on May 23, 2013